Loading clinical trials...
Loading clinical trials...
A Multicenter, Open-Label, Phase III Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Emicizumab Given Every 4 Weeks (Q4W) in Patients With Hemophilia A
Conditions
Interventions
Emicizumab
Locations
17
United States
University of California Davis
Sacramento, California, United States
Indiana Hemophilia & Thrombosis center
Indianapolis, Indiana, United States
University of Michigan, C.S. Mott Children's Hospital
Ann Arbor, Michigan, United States
Univ of N Carolina Chapel Hill; Hematology/Oncology
Chapel Hill, North Carolina, United States
Royal Brisbane Hospital; Clinical Haematology
Brisbane, Queensland, Australia
Royal Adelaide Hospital; Haematology Clinical Trials
Adelaide, South Australia, Australia
Start Date
January 30, 2017
Primary Completion Date
December 15, 2017
Completion Date
June 29, 2022
Last Updated
January 11, 2023
NCT07226206
NCT05987449
NCT04645199
NCT06703606
NCT06702579
NCT03818763
Lead Sponsor
Hoffmann-La Roche
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions